Avaleht › KOKH › Texas › Dallas
KOKH kliinilised uuringud linnas Dallas, TX
12 uuringut haiguse KOKH jaoks otsivad osalejaid linnas Dallas ja selle ümbruses (umbes 30 miili raadiuses). Avage uuring, et näha, kes saab osaleda ja kuidas võtta ühendust uuringumeeskonnaga.
Ametlik uuringutekst (inglise keeles)
Otsite osalejaid uuringusse? Esitlege seda selle lehe tipus – $99 30 päeva eest →
A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease
VärbamineFaas 3
- Research Site, Dallas
Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD), Characterized by an Eosinophilic Phenotype
VärbamineFaas 3
- IntraCare- Site Number : 8400034, Dallas
Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic Phenotype
VärbamineFaas 3
- Texas Health Presbyterian Hospital Dallas- Site Number : 8400032, Dallas
An Evaluation of the AeriSeal System for CONVERTing Collateral Ventilation Status in Patients With Severe Emphysema
Värbamine
- University of Texas Southwestern, Dallas
A Study to Investigate the Effect of AZD6793 in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease
VärbamineFaas 2
- Research Site, Dallas
A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00006)
VärbamineFaas 3
- Research Site, Dallas
A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate to Severe Chronic Obstructive Pulmonary Disease
VärbamineFaas 2/3
- Alina Clinical Trials, LLC., Dallas
A Non-inferiority Pharmacokinetic and Safety/Tolerability Study of Two Different Doses of Weekly SC Alpha1-PI 15% Compared With Corresponding Standard IV Alpha1-PI in Participants With Alpha1-Antitrypsin Deficiency (AATD)
VärbamineFaas 3
- GC2501 Study Site 109, Dallas
STRIVE Post-Market Registry Study
VärbamineVaatlusuuring
- Baylor Scott & White Research Institute, Dallas
- University of Texas Southwestern, Dallas
eValuating the Efficacy and Safety of InitiatinG depemokImab earLy therApy iN Chronic Obstructive Pulmonary Disorder (COPD) With Type 2 Inflammation
VärbamineFaas 3
- GSK Investigational Site, Dallas
Collection of Blood From Healthy Patients, Patients With Benign Disease and Patients With Cancer
VärbamineVaatlusuuring
- Liver Center of Texas, Dallas
Depemokimab as an Extended treatmeNt Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA-2)
VärbamineFaas 3
- GSK Investigational Site, Dallas
KOKH uuringud teistes linnades
- Philadelphia, PA23 uuringut
- Miami, FL18 uuringut
- Birmingham, AL17 uuringut
- Boston, MA17 uuringut
- Houston, TX15 uuringut
- Orlando, FL15 uuringut
- Baltimore, MD14 uuringut
- Chicago, IL14 uuringut
- Pittsburgh, PA12 uuringut
- New York City, NY11 uuringut
- Ann Arbor, MI10 uuringut
- Winston-Salem, NC9 uuringut
Muud uuringud linnas Dallas
- Rinnavähk55 uuringut
- Mitteväikerakuline kopsuvähk52 uuringut
- Metastaatiline vähk42 uuringut
- Südamepuudulikkus42 uuringut
- Vähk (kõik liigid)37 uuringut
- Eesnäärmevähk36 uuringut
- Käär- ja pärasoolevähk33 uuringut
- Rasvumine30 uuringut
- Munasarjavähk28 uuringut
- Põievähk27 uuringut
- Kopsuvähk27 uuringut
- Endomeetriumivähk24 uuringut
Allikas ClinicalTrials.gov, andmed saadud 4. okt 2026. Igal uuringul on oma osalemiskõlblikkuse tingimused; uuringumeeskond otsustab, kes saab osaleda.